nx-1607
nurix therapeutics
['marker ', 'nurix']
we presented six posters at this year s annual meeting, which included initial biomarker data from the ongoing phase 1 trial of our first-in-class oral cbl-b inhibitor, nx-1607. learn more: #sitc22 